Telomir Pharmaceuticals Secures Global Rights to Telomir-1

In a strategic move, Telomir Pharmaceuticals, Inc. announced a binding Letter of Intent to acquire TELI Pharmaceuticals, securing worldwide rights to Telomir-1. This agreement, which includes up to $5 million in potential shareholder contributions, aligns Telomir's U.S. rights with TELI's international intellectual property, consolidating control under a single entity.

Telomir-1, a small-molecule therapy targeting epigenetic drivers in cancer and age-related diseases, is showing promise in various preclinical models. The expanded global rights allow Telomir to explore partnerships and licensing opportunities on a broader scale, potentially tapping into robust markets where oncology spending is expected to reach $409 billion by 2028.

The transaction underscores Telomir's commitment to advancing its therapeutic reach across oncology, metabolic and degenerative diseases, and positions the company for significant long-term value creation.